U.S. stocks drifted higher following big rallies for markets in Asia earlier in the day.

Federal regulators are telling drugmakers to remove label warnings about potential suicidal thoughts and behaviors from their blockbuster weight-loss drugs.

U.S. regulators have approved a pill version of the weight-loss drug Wegovy.

Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain challenging for patients without insurance.

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war against Novo Nordisk.

President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy.

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera.

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera.

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a bidding war over another drugmaker.

Wall Street rolled to more records, led by a rally for technology stocks.

Wall Street held near its records.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy.

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance.

U.S. stocks rose to turn what would have been one of the market’s worst weeks of the year into just a pretty bad one.

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6, when combined with diet and exercise.

The World Health Organization and drugmaker Eli Lilly and Co. are warning patients to be wary of fake versions of weight-loss and diabetes medicines.

The popular weight-loss drug Wegovy can now be used to reduce the risk of stroke, heart attacks and other serious heart problems in patients who are overweight or who have obesity.

The manager of the world’s largest sovereign wealth fund is pledging to push major oil and gas companies to speed up preparations for the “inescapable” transition away from fossil fuels.

Many people may be considering using Ozempic, Wegovy or another popular drug to shed some pounds, but one local woman says all that demand could be putting her heart health at risk.

A new federal study finds that people taking popular diabetes and obesity drugs Ozempic and Wegovy had a lower risk of suicidal thoughts than those taking other medications to treat the same conditions.

Obesity rates in the U.S. have been rising steadily for well over a decade and some of the world’s biggest drug developers are tapping into the growing treatment market.

A new large study finds that the popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in certain patients.

Eli Lilly’s diabetes treatment Mounjaro, which is widely used for weight loss, raked in nearly $1 billion in second-quarter sales, or more than $200 million above what Wall Street had expected.

Losing significant amounts of weight may soon be as easy as taking a daily pill.

Novo Nordisk will start slashing some U.S. insulin prices up to 75% next year, following a path set earlier this month by rival Eli Lilly.

California says it will sue the companies that make and promote much of the nation's insulin.

Regulators say a new version of a popular diabetes medicine can be sold as a weight-loss drug in the U.S. The Food and Drug Administration on Friday approved Wegovy.